CAM
BOLD

Cormorant Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Cormorant Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50,000
Closed -$1.41M – 86
2019
Q3 		$1.41M Sell
50,000
-25,000
-33% -$853K 0.09% 67
2019
Q2 		$2.84M Sell
75,000
-25,000
-25% -$960K 0.16% 64
2019
Q1 		$3.9M Sell
100,000
-21,797
-18% -$625K 0.26% 53
2018
Q4 		$2.6M Sell
121,797
-3,203
-3% -$82.6K 0.21% 61
2018
Q3 		$4.95M Sell
125,000
-197,945
-61% -$7.38M 0.32% 50
2018
Q2 		$12.3M Hold
322,945
– – 0.91% 33
2018
Q1 		$9.7M Sell
322,945
-14,931
-4% -$505K 0.72% 28
2017
Q4 		$10.6M Buy
337,876
+14,331
+4% +$393K 1.11% 26
2017
Q3 		$9.06M Hold
323,545
– – 1.6% 22
2017
Q2 		$6.19M Sell
323,545
-101,115
-24% -$1.62M 1.03% 27
2017
Q1 		$7.24M Sell
424,660
-25,000
-6% -$404K 1.05% 32
2016
Q4 		$8.21M Hold
449,660
– – 1.11% 28
2016
Q3 		$8.01M Buy
+449,660
New +$6.82M 0.88% 37

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Cormorant Asset Management's BOLD Position: Q4 2019 in Review

Cormorant Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 50,000 shares — an estimated $1.41M sold.

Cormorant Asset Management first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $12.3M in Q2 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Cormorant Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Cormorant Asset Management sold 50,000 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $1.41M.
  • Cormorant Asset Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
  • Cormorant Asset Management's Audentes Therapeutics, Inc position peaked at $12.3M in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.